
Alpha and Omega Semiconductor Reports Financial Results for Fiscal Fourth Quarter and Fiscal Year Ended June 30, 2025
The results for the fiscal fourth quarter ended June 30, 2025 were as follows:
GAAP Financial Comparison
Quarterly
(in millions, except percentage and per share data)
(unaudited)
Three Months Ended
June 30, 2025
March 31, 2025
June 30, 2024
Revenue
$
176.5
$
164.6
$
161.3
Gross Margin
23.4
%
21.4
%
25.7
%
Operating Loss
$
(11.6
)
$
(10.7
)
$
(1.5
)
Net Loss
$
(77.1
)
$
(10.8
)
$
(2.7
)
Net Loss Per Share - Diluted
$
(2.58
)
$
(0.37
)
$
(0.09
)
Expand
Non-GAAP Financial Comparison
Quarterly
(in millions, except percentage and per share data)
(unaudited)
Three Months Ended
June 30, 2025
March 31, 2025
June 30, 2024
Revenue
$
176.5
$
164.6
$
161.3
Non-GAAP Gross Margin
24.4
%
22.5
%
26.4
%
Non-GAAP Operating Income (Loss)
$
2.3
$
(2.7
)
$
3.2
Non-GAAP Net Income (Loss)
$
0.7
$
(2.9
)
$
2.6
Non-GAAP Net Income (Loss) Per Share - Diluted
$
0.02
$
(0.10
)
$
0.09
Expand
The non-GAAP financial measures in the schedule above and under the section "Financial Results for Fiscal Q4 Ended June 30, 2025" below exclude the effect of share-based compensation expenses, amortization of purchased intangible, settlement and legal costs related to government investigation, equity method investment loss (income) from equity investee, and income tax effect of non-GAAP adjustments in each of the periods presented, as well as gain on change of equity interest in the equity method investment for the three months ended March 31, 2025, and impairment of the equity method investment and impairment of long-lived assets for the three months ended June 30, 2025. A detailed reconciliation of GAAP and non-GAAP financial measures is included at the end of this press release.
The results for the fiscal year ended June 30, 2025 and 2024 were as follows:
Non-GAAP Financial Comparison
Annually
(in millions, except percentage and per share data)
(unaudited)
Year Ended June 30,
2025
2024
Revenue
$
696.2
$
657.3
Non-GAAP Gross Margin
24.2
%
27.2
%
Non-GAAP Operating Income
$
10.4
$
21.7
Non-GAAP Net Income
$
7.0
$
18.5
Non-GAAP Net Income Per Share - Diluted
$
0.22
$
0.62
Expand
The non-GAAP financial measures in the schedule above exclude the effect of share-based compensation expenses, amortization of purchased intangible, settlement and legal costs related to government investigation, equity method investment loss from equity investee, and income tax effect of non-GAAP adjustments for fiscal years ended June 30, 2025 and 2024, as well as gain on change of equity interest in the equity method investment, impairment of the equity method investment, and impairment of long-lived assets for the fiscal year ended June 30, 2025. A detailed reconciliation of GAAP and non-GAAP financial measures is included at the end of this press release.
Financial Results for Fiscal Q4 Ended June 30, 2025
Revenue was $176.5 million, an increase of 9.4% from the same quarter last year and an increase of 7.2% quarter-over-quarter.
GAAP gross margin was 23.4%, down from 25.7% year-over-year and up from 21.4% in the prior quarter.
Non-GAAP gross margin was 24.4%, down from 26.4% from the same quarter last year and up from 22.5% in the prior quarter.
GAAP operating expenses were $52.9 million, up from $45.8 million in the prior quarter and up from $42.9 million from the same quarter last year.
Non-GAAP operating expenses were $40.9 million, up from $39.7 million from last quarter and up from $39.3 million from the same quarter last year.
GAAP operating loss was $11.6 million, up from $1.5 million from the same quarter last year and up from $10.7 million in the prior quarter.
Non-GAAP operating income was $2.3 million as compared to $3.2 million for the same quarter last year and an operating loss of $2.7 million from last quarter.
GAAP net loss per share was $2.58, compared to $0.37 for the prior quarter and $0.09 per share for the same quarter last year.
Non-GAAP earnings per share was $0.02, compared to $0.10 net loss per share for the prior quarter and $0.09 net earnings per share for the same quarter last year.
Consolidated cash flow used in operating activities was $2.8 million, as compared to $7.4 million of consolidated cash flow provided by operating activities in prior quarter.
The Company closed the quarter with $153.1 million of cash and cash equivalents.
AOS Chief Executive Officer Stephen Chang commented, 'Our fiscal Q4 results came in at the high-end of our guidance, led by strength in Computing as A.I. and graphics revenue reached record levels, alongside PC-related pull-ins as a result of tariff uncertainties, as well as continued momentum in wearables. These results underscore our ability to execute in a dynamic environment and demonstrate the growing impact of our total solutions strategy across high-performance applications.'
Mr. Chang concluded, 'Looking into the September quarter, we anticipate continued growth led by seasonal strength in Communications and steady demand in PCs and wearables. While macroeconomic and geopolitical uncertainties remain, our differentiated technology, broadening product portfolio, and deepening customer relationships position AOS well to deliver long-term growth through increased market share and BOM content across an expanding range of applications and end markets.'
Business Outlook for Fiscal Q1 Ending September 30, 2025
The following statements are based on management's current expectations. These statements are forward-looking, and actual results may differ materially. AOS undertakes no obligation to update these statements.
Revenue is expected to be $183 million plus or minus $10 million.
GAAP gross margin is expected to be 23.8% plus or minus 1%. Non-GAAP gross margin is expected to be 24.4% plus or minus 1%.
GAAP operating expenses are expected to be in the range of $47.5 million, plus or minus $1 million. Non-GAAP operating expenses are expected to be in the range of $41.0 million plus or minus $1 million.
Interest income is expected to be $0.5 million higher than interest expense, and
Tax expense is expected to be in the range of $1.0 million to $1.3 million.
Conference Call and Webcast
AOS plans to hold an investor teleconference and live webcast to discuss the financial results for the fiscal fourth quarter and the fiscal year ended June 30, 2025 today, August 6, 2025 at 2:00 p.m. PT / 5:00 p.m. ET. To listen to the live conference call, please dial +1 (844) 200-6205 or +1 (929) 526-1599 if dialing from outside the United States and Canada. The access code is 992322. A live webcast of the call will also be available in the "Events & Presentations" section of the Company's investor relations website, http://investor.aosmd.com. The webcast replay will be available for seven days after the live call on the same website. In addition, a copy of the script of management's prepared remarks and a live webcast of the call will also be available in the "Events & Presentations" section of the Company's investor relations website, http://investor.aosmd.com.
Forward Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management's judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, market trends in the semiconductor industry and growth in calendar year 2025, our ability to outperform market, seasonality of our business, our ability to sustain growth and expand our end markets, macro and geopolitical uncertainties, our projected amount of revenue, gross margin, operating income (loss), income tax expenses, net income (loss), and share-based compensation expenses, non-GAAP gross margin, non-GAAP operating expenses, income tax expenses, our ability to grow our sales, market share and BOM content, and other information under the section entitled 'Business Outlook for Fiscal Q1 Ending September 30, 2025.' Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the state of semiconductor industry and seasonality of our markets; decline of PC markets; our lack of control over the joint venture in China; difficulties and challenges in executing our diversification strategy into different market segments; ordering pattern from distributors and seasonality; changes in regulatory environment, including tariff and trade policies; our ability to introduce or develop new and enhanced products that achieve market acceptance; government policies on our business operations in China; the actual product performance in volume production; the quality and reliability of our product, our ability to achieve design wins; the general business and economic conditions; our ability to maintain factory utilization at a desirable level; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 to be filed by AOS with the SEC and other periodic reports we filed with the SEC. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today's date, unless otherwise stated, and AOS undertakes no duty to update such information, except as required under applicable law.
Use of Non-GAAP Financial Measures
To supplement our unaudited consolidated financial statements presented on a basis consistent with U.S. GAAP, we disclose certain non-GAAP financial measures for our historical performance, including non-GAAP gross profit, gross margin, operating expenses, operating income (loss), net income (loss), diluted earnings per share ('EPS') and EBITDAS. These supplemental measures exclude, among other items, share-based compensation expenses, legal and professional fees related to government investigation, amortization of purchased intangible, impairment of long-lived assets, gain on change of the equity interest in the JV Company, impairment on equity investment, income tax effect of non-GAAP adjustments and equity method investment loss (income) from equity investee. We also disclose certain non-GAAP financial measures in our financial guidance for the next quarter, including non-GAAP gross margin and non-GAAP operating expenses. We believe that these historical and forward-looking non-GAAP financial measures provide useful information to both management and investors by excluding certain items and expenses that are not indicative of our core operating results or do not reflect our normal business operations. In addition, our management uses non-GAAP measures to compare our performance relative to forecasts and to benchmark our performance externally against competitors. Our use of non-GAAP financial measures has certain limitations in that such non-GAAP financial measures may not be directly comparable to those reported by other companies. For example, the terms used in this press release, such as non-GAAP net income (loss) or non-GAAP operating expenses, do not have a standardized meaning. Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of our performance in relation to other companies. In addition, we included the amount of income tax effect of non-GAAP adjustments in the non-GAAP net income (loss) reconciliation table for all periods presented as management believes that such non-GAAP presentation provides useful information to investors, even though the amounts are not significant. We seek to compensate for the limitation of our non-GAAP presentation by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable U.S. GAAP measures both in the text in this press release and in the tables attached hereto. Investors are encouraged to review the related U.S. GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures.
About Alpha and Omega Semiconductor
Alpha and Omega Semiconductor Limited, or AOS, is a designer, developer, and global supplier of a broad range of discrete power devices, wide bandgap power devices, power management ICs, and modules, including a wide portfolio of Power MOSFET, SiC, IGBT, IPM, TVS, HV Gate Drivers, Power IC, and Digital Power products. AOS has developed extensive intellectual property and technical knowledge that encompasses the latest advancements in the power semiconductor industry, which enables us to introduce innovative products to address the increasingly complex power requirements of advanced electronics. AOS differentiates itself by integrating its Discrete and IC semiconductor process technology, product design, and advanced packaging know-how to develop high-performance power management solutions. AOS' portfolio of products targets high-volume applications, including personal computers, graphics cards, data centers, AI servers, smartphones, consumer and industrial motor controls, TVs, lighting, automotive electronics, and power supply units for various equipment. For more information, please visit www.aosmd.com.
The following unaudited consolidated financial statements are prepared in accordance with U.S. GAAP.
Alpha and Omega Semiconductor Limited
Condensed Consolidated Balance Sheets
(in thousands, except par value per share)
(unaudited)
June 30, 2025
ASSETS
Current assets:
Cash and cash equivalents
$
153,079
$
175,127
Restricted cash
419
413
Accounts receivable, net
34,772
12,546
Inventories
189,677
195,750
Other current assets
16,604
14,165
Total current assets
394,551
398,001
Property, plant and equipment, net
314,097
336,619
Operating lease right-of-use assets, net
21,288
25,050
Intangible assets, net
269
3,516
Equity method investment
279,122
356,039
Deferred income tax assets
599
549
Other long-term assets
22,766
25,239
Total assets
$
1,032,692
$
1,145,013
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable
$
60,044
$
45,084
Accrued liabilities
57,416
72,371
Payable related to equity investee, net
15,809
13,682
Income taxes payable
1,790
2,798
Short-term debt
11,852
11,635
Deferred revenue
—
2,591
Finance lease liabilities
1,007
935
Operating lease liabilities
4,978
5,137
Total current liabilities
152,896
154,233
Long-term debt
14,872
26,724
Income taxes payable - long-term
4,201
3,591
Deferred income tax liabilities
13,192
26,416
Finance lease liabilities - long-term
1,274
2,282
Operating lease liabilities - long-term
16,925
20,499
Other long-term liabilities
7,000
19,661
Total liabilities
210,360
253,406
Commitments and contingencies
Shareholders' Equity:
Preferred shares, par value $0.002 per share:
Authorized: 10,000 shares; issued and outstanding: none at June 30, 2025 and 2024
—
—
Common shares, par value $0.002 per share:
Authorized: 100,000 shares; issued and outstanding: 37,127 shares and 30,009 shares, respectively at June 30, 2025 and 36,107 shares and 28,969 shares, respectively at June 30, 2024
74
72
Treasury shares at cost; 7,118 shares at June 30, 2025 and 7,138 shares at June 30, 2024
(79,058
)
(79,213
)
Additional paid-in capital
379,779
353,109
Accumulated other comprehensive loss
(12,390
)
(13,419
)
Retained earnings
533,927
631,058
Total shareholders' equity
822,332
891,607
Total liabilities and shareholders' equity
$
1,032,692
$
1,145,013
Expand
Alpha and Omega Semiconductor Limited
Selected Cash Flow Information
(in thousands)
(unaudited)
Fiscal Year Ended June 30,
2025
2024
Net cash provided by operating activities
$
29,668
$
25,710
Net cash used in investing activities
(36,441
)
(35,744
)
Net cash used in financing activities
(15,496
)
(9,903
)
Effect of exchange rate changes on cash, cash equivalents and restricted cash
227
(126
)
Net decrease in cash, cash equivalents and restricted cash
(22,042
)
(20,063
)
Cash, cash equivalents and restricted cash at beginning of year
175,540
195,603
Cash, cash equivalents and restricted cash at end of year
$
153,498
$
175,540
Expand
Alpha and Omega Semiconductor Limited
(in thousands, except percentages and per share data)
(unaudited)
Three Months Ended
Fiscal Year Ended
June 30,
2025
March 31,
2025
June 30,
2024
June 30,
2025
June 30,
2024
GAAP gross profit
$
41,290
$
35,177
$
41,437
$
161,004
$
171,918
Share-based compensation
1,039
1,047
294
4,224
3,434
Amortization of purchased intangible
811
812
812
3,247
3,247
Non-GAAP gross profit
$
43,140
$
37,036
$
42,543
$
168,475
$
178,599
Non-GAAP gross margin as a % of revenue
24.4
%
22.5
%
26.4
%
24.2
%
27.2
%
GAAP operating expense
$
52,908
$
45,835
$
42,936
$
189,440
$
175,674
Share-based compensation
6,542
6,089
3,273
25,345
18,207
Settlement and legal costs related to government investigation
4,461
54
352
4,977
524
Impairment of long-lived assets
1,045
—
—
1,045
—
Non-GAAP operating expense
$
40,860
$
39,692
$
39,311
$
158,073
$
156,943
GAAP operating loss
$
(11,618
)
$
(10,658
)
$
(1,499
)
$
(28,436
)
$
(3,756
)
Share-based compensation
7,581
7,136
3,567
29,569
21,641
Amortization of purchased intangible
811
812
812
3,247
3,247
Settlement and legal costs related to government investigation
4,461
54
352
4,977
524
Impairment of long-lived assets
1,045
—
—
1,045
—
Non-GAAP operating income (loss)
$
2,280
$
(2,656
)
$
3,232
$
10,402
$
21,656
Non-GAAP operating margin as a % of revenue
1.3
%
(1.6
)%
2.0
%
1.5
%
3.3
%
GAAP net loss
$
(77,059
)
$
(10,807
)
$
(2,732
)
$
(96,976
)
$
(11,081
)
Share-based compensation
7,581
7,136
3,567
29,569
21,641
Amortization of purchased intangible
811
812
812
3,247
3,247
Gain on change of equity interest in equity method investment
—
(505
)
—
(505
)
—
Equity method investment loss (gain) from equity investee
(302
)
260
704
1,526
4,789
Settlement and legal costs related to government investigation
4,461
54
352
4,977
524
Impairment of equity method investment
76,784
—
—
76,784
—
Impairment of long-lived assets
1,045
—
—
1,045
—
Income tax effect of non-GAAP adjustments
(12,584
)
148
(78
)
(12,670
)
(627
)
Non-GAAP net income (loss)
$
737
$
(2,902
)
$
2,625
$
6,997
$
18,493
Non-GAAP net margin as a % of revenue
0.4
%
(1.8
)%
1.6
%
1.0
%
2.8
%
GAAP net loss
$
(77,059
)
$
(10,807
)
$
(2,732
)
$
(96,976
)
$
(11,081
)
Share-based compensation
7,581
7,136
3,567
29,569
21,641
Amortization and depreciation
15,447
18,259
13,908
62,396
53,757
Equity method investment loss (gain) from equity investee
(302
)
260
704
1,526
4,789
Impairment of equity method investment
76,784
—
—
76,784
Interest income
(956
)
(927
)
(1,295
)
(4,283
)
(5,168
)
Interest expense
530
596
883
2,639
3,982
Income tax expense (benefit)
(11,567
)
660
1,006
(8,625
)
3,649
EBITDAS
$
10,458
$
15,177
$
16,041
$
63,030
$
71,569
GAAP diluted net loss per share
$
(2.49
)
$
(0.37
)
$
(0.09
)
$
(3.10
)
$
(0.37
)
Share-based compensation
0.25
0.24
0.12
0.95
0.72
Amortization of purchased intangible
0.03
0.03
0.03
0.10
0.11
Gain on change of equity interest in equity method investment
—
(0.02
)
—
(0.02
)
—
Equity method investment loss (gain) from equity investee
(0.01
)
0.01
0.02
0.05
0.16
Settlement and legal costs related to government investigation
0.14
0.00
0.01
0.16
0.02
Impairment of equity method investment
2.48
—
—
2.46
—
Impairment of long-lived assets
0.03
—
—
0.03
—
Income tax effect of non-GAAP adjustments
(0.41
)
0.01
(0.00
)
(0.41
)
(0.02
)
Non-GAAP diluted net income (loss) per share
$
0.02
$
(0.10
)
$
0.09
$
0.22
$
0.62
Weighted average number of common shares used to compute GAAP diluted net income (loss) per share
29,924
29,530
28,879
29,405
28,236
Weighted average number of common shares used to compute Non-GAAP diluted net income (loss) per share
31,009
29,530
30,463
31,239
30,052
Expand
Alpha and Omega Semiconductor Limited
Reconciliation of GAAP to Non-GAAP Outlook
For Fiscal Q1 Ending September 30, 2025
(in millions, except percentages)
GAAP gross margin
23.8
%
Estimated impact of share-based compensation expense
0.6
%
Non-GAAP gross margin
24.4
%
GAAP operating expenses
$
47.5
Estimated stock-based compensation expense
(6.5
)
Non-GAAP operating expenses
$
41.0
Expand
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
If You Invested $10K In Micron Technology Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Micron Technology Inc. (NASDAQ:MU) designs, develops, manufactures, and sells memory and storage products globally. It is set to report its Q4 2025 earnings on Sept. 24. Wall Street analysts expect the company to post EPS of $2.51, up from $1.18 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $10.73 billion, up from $7.75 billion a year earlier. Don't Miss: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. If You Bought Micron Technology Stock 10 Years Ago The company's stock traded at approximately $18.91 per share 10 years ago. If you had invested $10,000, you could have bought roughly 529 shares. Currently, shares trade at $108.16, meaning your investment's value could have grown to $57,197 from stock price appreciation alone. However, Micron Technology also paid dividends during these 10 years. Micron Technology's dividend yield is currently 0.43%. Over the last 10 years, it has paid about $1.79 in dividends per share, which means you could have made $947 from dividends alone. Summing up $57,197 and $947, we end up with the final value of your investment, which is $58,144. This is how much you could have made if you had invested $10,000 in Micron Technology stock 10 years ago. This means a total return of 481.44%. In comparison, the S&P 500 total return for the same period is 258.20%. Trending: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— What Could The Next 10 Years Bring? Micron Technology has a consensus rating of "Buy" and a price target of $149.07 based on the ratings of 28 analysts. The price target implies more than 37% potential upside from the current stock price. The company on June 25 announced its Q3 2025 earnings, posting revenues of $9.3 billion, beating the consensus estimate of $8.87 billion. The company reported adjusted EPS of $1.91, above the consensus of $1.60. Micron expects Q4 revenue of $10.7 billion, plus or minus $300 million, versus estimates of $9.88 billion. Adjusted EPS is expected to be $2.50, plus or minus $0.15, versus the consensus of $2.01 per out this article by Benzinga for P/E ratio insights for Micron Technology. Given the historical stock price appreciation and expected upside potential, growth-focused investors may find Micron Technology stock attractive. Furthermore, they can benefit from the company's modest dividend yield of 0.43%. Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's , starting article If You Invested $10K In Micron Technology Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Why Iovance Biotherapeutics Stock Plummeted Today
Key Points Investors were hardly pleased by the company's double miss on second-quarter results. At least its revenue guidance was in line with expectations. 10 stocks we like better than Iovance Biotherapeutics › Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (NASDAQ: IOVA). The company published its second-quarter earnings after market close the previous day, and the market reacted by trading the stock down by more than 20%. Amtagvi leads the way Iovance, a commercial-stage biotech that's focused on cell therapies for cancer treatment, reported slightly under $60 million in revenue for the period, which was nearly double the $31 million it earned in the same quarter of 2024. All of this is derived from sales of two products: Amtagvi and Proleukin. The former was by far the company's star, with over $54 million in sales. The steep increase in sales didn't filter down into a net profit, however. In fact, Iovance's GAAP (generally accepted accounting principles) net loss deepened during the quarter, coming in at almost $112 million ($0.33 per share) from the year-ago deficit of $97 million. Also, analysts were expecting Iovance to boost its top line even more. Their consensus estimate for revenue was a shade over $67 million. As for net loss, they were modeling a deficit of only $0.28 per share. In its earnings release, Iovance nevertheless sounded a bullish note about the future of its two commercialized products. It quoted CEO Frederick Vogt as saying that "Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing authorized treatment center growth continues and large community practices begin treating patients." No move on revenue guidance Investors might have liked to see that statement bolstered by a guidance raise. However, Iovance stuck to its existing forecast of $250 million to $300 million anchored, of course, by Amtagvi. The company pointed out that this is the first full year of Amtagvi sales, implying the future should be much rosier for the product. Do the experts think Iovance Biotherapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Iovance Biotherapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Plummeted Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Why Nektar Therapeutics Stock Popped 6% on Friday
Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Do the experts think Nektar Therapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nektar Therapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Popped 6% on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data